Growing Adoption of Targeted Therapy Driving Immunotherapy Drugs Market

In 2017, the global immunotherapy drugs market reached a value of $106.1 billion and is predicted to advance at a 13.6% CAGR during the forecast period (2018–2023). The market is growing because of the rising availability of biosimilars, surging prevalence of chronic diseases, increasing implementation of target therapy, and rising demand and development of mAbs. Immunotherapy is the treatment of a disease by enhancing, inducing, or suppressing an immune response for fighting against infection and disease. In terms of type, the immunotherapy drugs market is bifurcated into vaccines and checkpoint inhibitors.

Receive Sample Copy of this Report:https://www.psmarketresearch.com/market-analysis/immunotherapy-drugs-market/report-sample

Between these, the checkpoint inhibitors division held the largest share of the immunotherapy drugs market during the historical period (2013–2017) and is expected to dominate the market during the forecast period. Checkpoint inhibitors are preferred for the treatment of chronic diseases, since they offer better and effective treatment results. These drugs act directly on the site of action without delaying the effect of the medicine, which is why they are increasingly being adopted. On the basis of brand, the division is further classified into Enbrel, Remicade, Herceptin, Rituxan/MabThera, Humira, and others.

Make an Enquiry before Purchase:https://www.psmarketresearch.com/send-enquiry?enquiry-url=immunotherapy-drugs-market

Another primary factor which is contributing significantly to the growth of the immunotherapy drugs market is the rising implementation of target therapy. Targeted treatment provides various health benefits to the patients, which is why the adoption of these therapies is increasing. Healthcare providers are making use of targeted treatment for treating different chronic diseases, including cystic fibrosis, melanoma, leukemia, and lung cancer. For example, Herceptin drug is utilized as a targeted therapy for the treatment of adenocarcinoma of the stomach or gastroesophageal junction and breast cancer.

Out of all the regions, North America held the largest share of the immunotherapy drugs market during the historical period and is projected to retain its position during the forecast period. The reasons for this are the increasing prevalence of chronic diseases, rising per capita healthcare spending, growing geriatric population, and presence of major players in the region. The Asia-Pacific region is expected to witness the highest growth rate during the forecast period. This is ascribed to the rising number of research & development activities which are being conducted in the region.

Hence, the market is being driven by the increase in the implementation of target therapy and rising prevalence of chronic diseases.

About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.